Sarepta (SRPT) Sees Early Weakness, At-the-Market Offering In Focus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Sarepta Therapeutics (SRPT) Enters $40M At-The-Market Agreement with Citadel
September 4, 2012 5:07 PM EDTSarepta Therapeutics, Inc. (NASDAQ:... More
Sarepta Therapeutics (SRPT) Riding High On Successful Drug
August 30, 2012 8:08 AM EDTSarepta Therapeutics, Inc. (Nasdaq: SRPT) is higher yet again in pre-open trading Thursday as the company's Duchenne Muscular Dystrophy treatment continues to get positive,... More
